PSMA (clone 107.1A4), anti-human
€564.00
In stock
SKU
ARP-21-5237
Catalog Number: 21-5237
Size: 100 µg
Isotype: Mouse IgG1
Size: 100 µg
Isotype: Mouse IgG1
Background:
Prostate specific antigen (PSA) is the most widely used marker of prostate cancer. Immunoassays for PSA using monoclonal (MAb) or polyclonal antibodies have clinical appliCations, such as monitoring and early detection of prostate cancer. However, PSA is not a perfect tumor marker because Serum levels often are elevated in men with benign prostatic hyperplasia, prostatitis and other nonmalignant disorders and also because levels are not always elevated in individuals with early prostate cancer. 107-1A4 is a new prostate cancer-reactive MAb which can identify additional proteins that could be of value for the diagnosis and treatment of prostate cancer. It shows selective reactivity to prostate epithelial membrane antigens.
Clone: 107.1A4
Isotype: Mouse IgG1
Source: 107.1A4 is a Mouse monoclonal IgG1/k antibody derived by fusion of SP2/0-Ag14 Mouse myeloma cells with spleen cells from an immunized Mouse, using a two-phase immunization protocol involving the prostate cancer cell line LNCaP.
Reactivity: human
Specificity: 107.1A4 recognizes an antigen, which appeared to be distinct from those previously described and shows specific tumor targeting in preliminary in vivo studies. MAb 107-1A4 is suggested to recognize a distinct conformational and unique epitope in the extracellular domain of PSMA. PSMA is a type II membrane glycoprotein of 100kDa that has a short intracellular N-terminal domain (residues 1 to 18), a transmembrane region (residues 19 to 43) and a large extracellular domain consisting of residues 44 to 750.
Form: Each vial contains 100ul purified monoclonal antibody in PBS containing 0.09% sodium azide.
Applications: ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry (frozen), Immunohistochemistry (paraffin)
Storage: Store at 4C, or in small aliquots at -20C.
Prostate specific antigen (PSA) is the most widely used marker of prostate cancer. Immunoassays for PSA using monoclonal (MAb) or polyclonal antibodies have clinical appliCations, such as monitoring and early detection of prostate cancer. However, PSA is not a perfect tumor marker because Serum levels often are elevated in men with benign prostatic hyperplasia, prostatitis and other nonmalignant disorders and also because levels are not always elevated in individuals with early prostate cancer. 107-1A4 is a new prostate cancer-reactive MAb which can identify additional proteins that could be of value for the diagnosis and treatment of prostate cancer. It shows selective reactivity to prostate epithelial membrane antigens.
Clone: 107.1A4
Isotype: Mouse IgG1
Source: 107.1A4 is a Mouse monoclonal IgG1/k antibody derived by fusion of SP2/0-Ag14 Mouse myeloma cells with spleen cells from an immunized Mouse, using a two-phase immunization protocol involving the prostate cancer cell line LNCaP.
Reactivity: human
Specificity: 107.1A4 recognizes an antigen, which appeared to be distinct from those previously described and shows specific tumor targeting in preliminary in vivo studies. MAb 107-1A4 is suggested to recognize a distinct conformational and unique epitope in the extracellular domain of PSMA. PSMA is a type II membrane glycoprotein of 100kDa that has a short intracellular N-terminal domain (residues 1 to 18), a transmembrane region (residues 19 to 43) and a large extracellular domain consisting of residues 44 to 750.
Form: Each vial contains 100ul purified monoclonal antibody in PBS containing 0.09% sodium azide.
Applications: ELISA, Flow Cytometry, Immunocytochemistry, Immunohistochemistry (frozen), Immunohistochemistry (paraffin)
Storage: Store at 4C, or in small aliquots at -20C.
| Is Featured? | No |
|---|
Write Your Own Review